An interventional study of spectacles in Blindness,Visual Impairment, Refractive Error, Cataract, High Myopia, Aging, sponsored by Shanghai Eye Disease Prevention and Treatment Center. Recruiting at 1 site in China. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-24.
Sponsored by Shanghai Eye Disease Prevention and Treatment Center · Not applicable, Interventional, and Screening
Blindness and visual impairment severely impact the visual health and life quality of people, particularly the 2.566 million senior citizens aged at 65 and above in Shanghai. The main reason is uncorrected refractive error, of which, 62.1% can be solved through refractive correction. For this reason, the uncorrected refractive errors of 154,000 senior citizens in Shanghai can be taken as a priority among the public health issues to prevent blindness. Now, with the aim to reduce the prevalence rate of blindness and visual impairment, it is planned to establish a public health service mechanism in terms of refractive error screening and correction for the elderly by relying on Shanghai's three-level (city-district-community) eye diseases prevention network, using proper refractive correction technology, and moving related services forward to communities in order to screen, identity, and correct blindness and visual impairment caused by refractive errors as early as possible.
Exclusion Criteria:
Device: spectacles
dispending spectacles for uncorrected refractive error
best-corrected visual acuity (BCVA)
the prevalence of blindness and visual impairment
Time frame: 5 years
cataract surgery rate
cataract surgery rate of Shanghai older people
Time frame: 5 years
cataract surgery coverage rate
cataract surgery coverage rate of Shanghai cataract patients
Time frame: 5 years
visual impairment caused by high myopia
observing the rate of visual impairment caused by high myopia
Time frame: 5 years
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Eye Disease Prevention and Treatment Center